Phospholipid (Cardiolipin) Antibodies, IgG and IgM, Serum
Use
The test is useful for identifying clinical conditions such as unexplained arterial or venous thrombosis, certain pregnancy morbidities, systemic autoimmune rheumatic diseases like systemic lupus erythematosus, unexplained skin manifestations, unexplained thrombocytopenia, and potential nonbacterial, thrombotic endocarditis. It targets the detection of persistent anticardiolipin antibodies, which are pivotal in diagnosing antiphospholipid syndrome (APS).
Special Instructions
Not provided.
Limitations
Immunoassays for anticardiolipin antibodies may not fully distinguish between antibodies specific to antiphospholipid syndrome and those resulting from infections. Documentation of persistence, as per Sapporo guidance, is recommended to establish APS diagnosis. Variability between immunoassays can lead to different results, highlighting the need for harmonization and standardization.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
IgG and IgM Cardiolipin Antibodies
Analyte
LOINC Codes
- 24319-6 - Cardiolipin IgG+IgM Pnl Ser
- 3181-5 - Cardiolipin IgG Ser IA-aCnc
- 3182-3 - Cardiolipin IgM Ser IA-aCnc
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.4 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Storage Instructions
Refrigerated preferred for up to 21 days, can be frozen for the same period.
Causes for Rejection
Gross hemolysis, gross lipemia, and heat-treated specimens are reasons for rejection while gross icterus is acceptable.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |